Bladder cancer. The selection of patients for treatment by full‐dose irradiation
- 1 May 1985
- Vol. 55 (S9) , 2278-2284
- https://doi.org/10.1002/1097-0142(19850501)55:9+<2278::aid-cncr2820551435>3.0.co;2-#
Abstract
Cure of muscle-invading bladder carcinoma in 20% to 39% of patients using full-dose external beam irradiation has been reported by many institutions in the last 10 years. Local failure occurs in 50% of patients so treated, however, and successful selection criteria for bladder-sparing radiotherapy are necessary. Prognostic factors which have been identified to be associated with a relatively successful outcome using full-dose irradiation include (1) the clinical stages T2 and T3, (2) the absence of ureteral obstruction on initial intravenous pyelogram, (3) a visibly "complete" transurethral resection having been achieved, and (4) complete response of the local tumor to radiation. In addition, local tumor control appears to be related to total dose administered. Analysis of the results of precystectomy radiation therapy, where papillary tumor histology and small tumor size yielded improved survival, suggests that these characteristics also may prove to be beneficial in patients selected for full-dose irradiation. The four-field box technique has become accepted as the best method to treat patients using beams from linear accelerators or betatrons. The bladder and pelvic lymph nodes should be treated to 50.4 Gy in 1.8 Gy fractions, 5 days/week. A cone-down boost to the tumor volume only then is given for a total dose of 64.8 Gy to 68.4 Gy in 7.5 weeks. The posterior rectosigmoid should receive less than 60 Gy, and the anus and femoral head and neck should be limited to 45 to 50 Gy to avoid toxicity. Innovative approaches to treatment of muscle-invading bladder cancer now are being explored and include the use of intravesical misonidazole combined with fractionated external beam irradiation, and systemic cisplatin administration in combination with radiation. Techniques which have yielded good results in superficial bladder cancer include open interstitial implantation, intraoperative single-dose electron beam irradiation, and trans-Foley radium applications. Further prospective evaluations of clinical and histologic tumor characteristics, treatment techniques and doses reviewed here will be necessary before definitive selection criteria for treatment with full-dose irradiation are established.Keywords
This publication has 23 references indexed in Scilit:
- Radiation therapy and cystectomyUrology, 1984
- Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancerInternational Journal of Radiation Oncology*Biology*Physics, 1983
- Cancer of the urinary bladder category t2, t3, (NXM0) treated by interstitial radium implant: Second reportInternational Journal of Radiation Oncology*Biology*Physics, 1983
- Axillary sampling in the definitive treatment of breast cancer by radiation therapy and lumpectomyInternational Journal of Radiation Oncology*Biology*Physics, 1983
- Carcinoma of the urinary bladder category T3NxMo treated by the combination of radium implant and external irradiation: Second reportInternational Journal of Radiation Oncology*Biology*Physics, 1983
- Treatment of T3 Bladder Cancer: Controlled Trial of Pre-operative Radiotherapy and Radical Cystectomy Versus Radical Radiotherapy: Second Report and Review (for the Clinical Trials Group, Institute of Urology)British Journal of Urology, 1982
- Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomyInternational Journal of Radiation Oncology*Biology*Physics, 1981
- T3 Bladder Cancer-the Case for Salvage CystectomyBritish Journal of Urology, 1980
- The prognostic significance of ureteral obstruction in carcinoma of the bladderInternational Journal of Radiation Oncology*Biology*Physics, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958